Mechanisms involved in the potentiation of melphalan by the bioreductive bompound THNLA-1 in Vitro

Oncology Research

Volumn 11, Issue 8, 1999, Pages 345-357

  Papadopoulou, Maria V ^a   Khan, Shariq H ^a   Bloomer, William D ^b  

^a Radiation Medicine Institute   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Bioreductive drugs; Chemotherapy; Mechanisms; Potentiation; THNLA I

Indexed keywords

9 (3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO) 1,2,3,4 TETRAHYDROACRIDINE; 9-(3-(2-NITRO-1-IMIDAZOLYL)PROPYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE; ALKYLATING AGENT; BUTHIONINE SULFOXIMINE; DNA; DRUG DERIVATIVE; GLUTATHIONE; MELPHALAN; PROTEIN; RADIOSENSITIZING AGENT; RNA; TACRINE;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL HYPOXIA; CELL LINE; COMET ASSAY; COMPARATIVE STUDY; CRICETULUS; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG POTENTIATION; HAMSTER; METABOLISM; PROTEIN SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BUTHIONINE SULFOXIMINE; CELL CYCLE; CELL HYPOXIA; CELL LINE; COMET ASSAY; CRICETINAE; CRICETULUS; DNA; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; GLUTATHIONE; MELPHALAN; PROTEIN BIOSYNTHESIS; PROTEINS; RADIATION-SENSITIZING AGENTS; RNA; TACRINE;

EID: 0033289801     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Moulder, J. E.; Rockwell, S. Tumor hypoxia; its impact on cancer therapy. Cancer Metastasis Rev. 5:313-341; 1987.
2. Vaupel, P.; Schlenger, K.; Knoop, C.; Hockel, M. Oxygénations of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O, tension measurements. Cancer Res. 51:3316-3322; 1991.
3. Gatenby, R. A.; Kassler, H. B.; Rosenblum, J. S.; Coia, L. R.; Moldofsky, P. J.; Hartz, W. H.; Broder, G. I. Oxygen distribution in squamous cell carcinoma métastases and its relationship to outcome of radiation therapy. Int. J. Radial. Oncol. Biol. Phys. 14: 831-838; 1988.
4. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:45-50; 1993.
5. Siemann, D. W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiât. Oncol. Biol. Phys. 10:1585-1594; 1984.
6. Grau, C.; Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol. 13:301-309; 1988.
7. Kennedy, K. A. Hypoxie cells as specific drug targets for chemotherapy. Anticancer Drug Des. 2:181-194; 1987.
8. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res. 48:775-778; 1988.
9. Holden, S. A.; Teicher, B. A.; Ara, G.; Herman, T. S.; Coleman, C. N. Enhancement of alkylating agent activity by SR-4233 in FSalIC murine fibrosarcoma. J. Natl. Cancer Inst. 84:187-193; 1992.
10. Papadopoulou, M. V.; Miller, A.; Seskey, T.; Epperly, M. W.; Bloomer, W. D. Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiât. Oncol. Invest. 1:206-217; 1993.
11. Doric, M. J.; Brown, J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233} and cisplatin. Cancer Res. 53:4633-4636; 1993.
12. Siemann, D. W. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother. Oncol. 34:47-53; 1995.
13. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1: A DNA-targeted bioreductive agent as chcmosensitizer m vitro and in vivo. In vivo 10:49-58; 1996.
14. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1 as radio/ chcmoscnsilizer of EMT-6 tumors in mice. Dr. J. Cancer 74(Suppl. XXVII):S267-S270; 1996.
15. -cyclopenteno[b]quinoline hydrochloridc (NLCPQ-1). A novel DNA-affinic bioreductive agent as chcmosensitizer. I. Oncol. Res. 9:249-257; 1997.
16. Papadopoulou, M. V; Ji, M.; Bloomer, W. D. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of mclphalan, rJ.cDDP and cyclophosphamide in vivo. Int. J. Radial. Oncol. Biol. Phys. 42:775-779; 199S.
17. Marshall, J. L.; Figueira, M.; Dahut, W.; Rizvi, N.; Roemcling, R.; Hawkins M. J. Tirapazaminc plus cisplatin in the treatment of patients with breast cancer and other platinum resistant tumors. A phase II clinical trial. Cancer Thcr. l(4):237-243; 1998.
18. Treat, J.; Johnson, E.; Langer, C; Bclani, C.; Haynes, B.; Greenberg, R.; Rodriquez, R.; Drobins, P.; Miller, W.; Meehan, L.; McKcon, A.; Devine, J.; Rocmeling, R.; Viallet, J. Tirapazaminc with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study. J. Clin. Oncol. 16:3524-3527; 1998.-4
19. Papadopoulou, M. V.; Roscnzweig, H. S.; Doddi, M.: Bloomer, W. D. 9-[3-(2-Nitro-l-imidazolyl)propylamino-l,2,3,4-tetrahydroacridinc hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol. Res. 6:439-448; 1994.
20. -cyclopenteno[b]quinoline hydrochloride (NLCPQ-I). A novel DNA-affinic bioreduclivc agent as chemosensitizer: Mechanistic studies. II. Oncol. Res. 10:163-173; 1998.
21. Kramer, R. A.; Grccne, K.; Ahmad, S.; Vistica, D. T. Chemosensitization of L-phenyl-alaninc mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res. 47:1593-1597; 1987.
22. Russo, A.; Mitchell, J. B. Potentiation and protection of doxorubicin cytotoxicity by cellular glutathionc modulation. Cancer Treat. Rep. 69:1293-1296; 1985.
23. Murray, D.; Meyn, R. E. Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. Br. J. Cancer 47: 195-203; 1983.
24. Taylor, Y. C.; Evans, J. W.; Brown, J. M. Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res. 43:3175-3181; 1983.
25. Taylor, Y. C.; Bump, E. A.; Brown, J. M. Studies on the mechanism of chemosensitization by misonidazole in vitro. Int. J. Radial. Oncol. Biol. Phys. 8:705-708; 1982.
26. Olive, P. L. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreduclive drugs. I. Tirapazamine. Br. J. Cancer 71: 529-536; 1995.
27. Fairbairn, D. W.; Olive, P. L.; O'Neill, K. L. The comet assay: A comprehensive review. Mutât. Res. 339:37-59; 1995.
28. Tietze, F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glulathione: Applications to mammalian blood and other tissues. Anal. Biochcm. 27:502-522; 1969.
29. Ormerod, M. G.; Orr, R. M.; Peacock, J. H. The role of apoptosis in cell killing by cisplatin: A flow cylometry study. Br. J. Cancer 69:93-100; 1994.
30. Kohn, K. W.; Erickson, L. C.; Ewig, R. A. G.; Friedman, C. A. Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15:4629-4637; 1976.
31. Heller, D. P.; Raaphorst, G. P. The kinetics of cellular recovery in exponential and plateau growth phase human glioma cells following y-irradiation. Int. J. Radiât. Oncol. Biol. Phys. 30:383-390; 1994.
32. Olive, P. L. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreduclive drugs. II. RSU 1069. Br. J. Cancer 71:537-542; 1995.
33. Ross, W. E.; Ewig, R. A. G.; Kohn, K. W. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res. 38:1502-1506; 1978.
34. Schröder, C. P.; Godwin, A. K.; O'Dwycr, P. J.; Tew, K. D.; Hamilton, T. C; Ozols, R. F. Glutathionc and drug resistance (review). Cancer Invest. 14:158-168; 1996.
35. Hamilton, T. C.; Winker, M. A.; Louie, K. G.; Batist, G.; Bohrens, B. C; Tsuruo, T.; Grotzinger, K. R.; McKoy, W. M.; Young, R. C.; Ozols, R. F. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. Biochcm. Pharmacol. 34:2583-2586; 1985.
36. Meister, A. Metabolism and function of glutathione. Trends Biochem. Sci. 6:231-234, 1981.
37. Nio, Y.; Imai, S.; Shiraishi T.; Tsubono, M.; Morimoto, H.; Tseng, C.; Tobe, T. Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph node of patients evaluated by DNA synthesis inhibition assay. Cancer 65:1273-1278; 1990.
38. Liebmann, J. E.; Fisher, J.; Teague, D.; Cook, J. A. Sequence dependence of paclitaxel (taxol) combined with cisplatin or alkylators in human cancer cells. Oncol. Res. 6:25-31; 1994.
39. Orlandi, L.; Zaffaroni, N.; Bearzatto, A.; Costa, A.; Supino, R.; Vaglini, M.; Silvestrini, R. Effect of melphalan and hypcrthermia on cell cycle progression and cyclin Bl expression in human melanoma cells. Cell Prolif. 28:617-630; 1995.
40. Fernberg, J. O.; Lcwensohn, R.; Skog, S. Interphase cell death as related to the cell cycle of melphalan-treatcd human myeloma cells. Med. Oncol. Tumor Pharmacother. 8:63-67; 1991.
41. Gorczyca, W.; Gong, J.; Ardelt, B.; Traganos, F.; Darzynkiewicz, Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:3186-3192; 1993.
42. Millar, B. C; Tilby, M. J.; Ormcrod, M. G.; Payne, A. W.; Jinks, S.; Loverock, P. S. Comparative studies of total cross-linking, cell survival and cell cycle perturbations in Chinese hamster cells treated with alkylating agents in vitro. Biochem. Pharmacol. 35: 1163-1169; 1986.
43. Fcrnbcrg, J. O.; Lewensohn, R.; Skog, S. Cell cycle arrest and DNA damage after melphalan treatment of the human myeloma cell line RPMI 8226. Eur. J. Haematol. 47:161-167; 1991.